Cobra Biologics reported the installation of a 1000L HyClone single-use bioreactor (SUB) at the company’s center of excellence for mammalian antibody and recombinant protein production. This is the most recent development in the company's on-going expansion plans. The installation of the SUB technology is in response to an increased demand for contract manufacturing services and the drive to be a supplier of commercial antibodies and recombinant proteins.
Cobra’s expansion began with the acquisition of a purpose built aseptic manufacturing facility in 2011, providing fill and finish services for pre-filled syringes, vials, and freeze drying /lyophilization for biologics and pharmaceuticals.
Source: Cobra Biologics